A neuraminidase-targeting nanobody as a therapeutic candidate against influenza A and B viruses
F4-Fc demonstrates prophylactic and therapeutic efficacy against influenza A and B viruses, representing a promising antiviral drug candidate for influenza virus infection and demonstrating its antiviral efficacy in vitro and protective activity in vivo.